Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IVAX Insider Trading -- Ignore unavailable to you. Want to Upgrade?

To: flickerful who wrote (542)	2/27/1998 9:02:00 PM
From: 5,17,37,5,101,...	Read Replies (3) \| Respond to of 756

Despite that this is not really news, here is the article. Jackson DOW JONES NEWS SERVICE 14:06 Seldane, Generic Terfenadine Withdrawn From Market >HOE WASHINGTON (Dow Jones)--Hoechst Marion Roussel and Baker Norton Pharmaceuticals have volunatrily discontinued distribution and marketing of all terfenadine-containing antihistamine product lines in the U.S., the FDA said. Terfenadine-containing products, such as Seldane and Seldane-D, have been associated with rare but serious heart problems when taken with certain other drugs, including certain antibiotics and antifungals, FDA said in a statement. Last year, under pressure from the FDA, Hoechst Marion Roussel withdrew Seldane from the market because the risk of irregular heartbeats and other potentially fatal side effects outweighed the drug's benefits. The unit of German pharmaceuticals and chemicals giant Hoechst AG (HOE) has replaced Seldane with Allegra, which doesn't have the same dangerous side effects. Baker Norton is a unit of Ivax Corp. (IVX) -By Carl Johnston (202) 862-9294; E-Mail DowJWash@AOL.COM (END) DOW JONES NEWS 02-27-98 02:06 PM